Dendreon (DNDN +4.4%) jumps after the CHMP renders a positive opinion on Provenge for the...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN +4.4%) jumps after the CHMP renders a positive opinion on Provenge for the "treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer." It will be interesting to watch how analysts react given the drug's Q1 numbers.